BioNTech Analyst Ratings
Morgan Stanley Upgrades BioNTech to Overweight From Equalweight, Boosts Price Target to $145 From $93
BioNTech SE (BNTX) Receives a Hold From Morgan Stanley
BioNTech Analyst Ratings
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $131
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
BioNTech Price Target Raised to $150.00/Share From $96.00 by Jefferies
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $125 to $171
BioNTech Analyst Ratings
Jefferies Upgrades BioNTech SE (BNTX) to a Buy
Evercore ISI Sticks to Its Hold Rating for BioNTech SE (BNTX)
BioNTech SE (BNTX) Gets a Hold From TD Cowen
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
J.P. Morgan Upgrades BioNTech(BNTX.US) to Hold Rating, Announces Target Price $125
Buy Rating Affirmed for BioNTech SE Following Promising Clinical Trial Results in Oncology
BioNTech Is Maintained at Hold by Jefferies
BioNTech Analyst Ratings
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171